vimarsana.com
Home
Live Updates
Immunic Reports Positive Interim Data from Phase 2 CALLIPER
Immunic Reports Positive Interim Data from Phase 2 CALLIPER
Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis P...
Related Keywords
Switzerland ,
Russia ,
Ukraine ,
United States ,
America ,
Paula Schwartz ,
Edna Kaplan ,
Andreas Muehler ,
Jens Kuhle ,
Jessica Breu ,
Daniel Vitt ,
Immunic Inc ,
Exchange Commission ,
Rx Communications Group ,
University Hospital Basel ,
Nasdaq ,
Prnewswire Immunic Inc Nasdaq ,
Program In Relapsing Multiple Sclerosis Ongoing ,
Sclerosis Centre ,
Week Data ,
First Half ,
Patients Shows Improvements ,
Consistent Throughout ,
Overall Progressive Multiple Sclerosis Population ,
All Subtypes ,
Nfl Effect ,
Neuroprotective Potential ,
Brain Volume Data ,
Cohort Expected ,
Relapsing Multiple Sclerosis Ongoing ,
Conference Call ,
Held Tomorrow ,
Senior Physician ,
Neuroimmunology Unit ,
Multiple Sclerosis Centre ,
Chief Executive Officer ,
Chief Medical Officer ,
North America ,
Vidofludimus Calcium ,
Private Securities Litigation Reform Act ,
Annual Report ,
Investor Relations ,